All Articles
The FDA has given a green light for elementary school-age kids to get the updated booster doses made by Pfizer…
Pfizer asked U.S. regulators Monday to expand use of its updated COVID-19 booster shot to children ages 5 to 11.
Pfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization…
Only about 6% of youngsters ages 6 months through 4 years had gotten at least one dose of a COVID-19…
Temporary menstrual changes may be more of a side effect of the COVID-19 vaccine than previously understood, new research finds.
Pfizer announced Saturday that tweaking its COVID-19 vaccine to better target the omicron variant is safe and works.
The hope is that an extra shot will shore up protection for kids ages 5 to 11 as COVID-19 infections…
Nasal vaccines are tricky to develop and it’s not clear how quickly any could become available, but several are in…
Boosters given over the past few months will protect those vaccinated through this winter, but their effectiveness could dip by…
The U.S. is expanding COVID-19 boosters, ruling that 16- and 17-year-olds can get a third dose of Pfizer’s vaccine.
Pfizer said Wednesday that a booster dose of its COVID-19 vaccine may offer important protection against the new omicron variant.
Pfizer and Moderna announced that the Food and Drug Administration opened up COVID-19 booster shots to all adults.
The U.S. government will pay Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators…
The league recommendations called for those who got Johnson & Johnson vaccines originally to seek a Pfizer or Moderna booster.
Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent…
U.S. health officials gave the final signoff to Pfizer’s kid-size COVID-19 shot, a major expansion of the nation’s vaccination campaign.
Kid-size doses of Pfizer’s COVID-19 vaccine may be getting closer as government advisers on Tuesday began deliberating.
The Food and Drug Administration posted its analysis of Pfizer’s data ahead of a public meeting next week discussing the…
Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds.
U.S. regulators on Wednesday signed off on extending COVID-19 boosters to Americans who got the Moderna or Johnson & Johnson…